Thymalfasin 中文名称: 胸腺肽 alpha 1

别名: Zadaxin; Thymosin alpha1; Thymosin alpha 1; alpha1-Thymosin; Thymosin-alpha-1; 胸腺肽 alpha 1;胸腺 28 肽;胸腺肽(小牛);醋酸胸腺肽α1;胸腺阿尔法一;胸腺肽A-1;胸腺肽Α1(THYMOSINΑ1); 胸腺法新;胸腺法新;胸腺素α1(胸腺素a-1) 胸腺肽α1;胸腺肽;胸腺肽alpha 1, 胸腺28 肽;胸腺肽α1;胸腺肽α1 Thymosin α1 Acetate;胸腺肽α1 Thymosinα1Acetate;胸腺五肽;醋酸胸腺肽 Alpha1;胸腺肽 α1;胸腺28肽杂质;醋酸胸腺α1

目录号: V29874 纯度: ≥98%

COA 产品数据产品说明书 SDS

Thymalfasin (thymosin-alpha 1) 是一种免疫调节化合物，可增强 Thl 免疫反应。

Thymalfasin CAS号: 62304-98-7
产品类别: Influenza Virus

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
1mg
5mg
10mg
25mg
50mg
100mg
500mg
1g
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

点击了解更多

与全球5000+客户建立关系
覆盖全球主要大学、医院、科研院所、生物/制药公司等
产品被大量CNS顶刊文章引用

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

纯度/质量控制文件

批次：

纯度: =99.33%

COA

MSDS

HPLC

产品说明书

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

Thymalfasin (thymosin-alpha 1) 是一种免疫调节化合物，可增强 Thl 免疫反应。

生物活性&实验参考方法

靶点	Immunomodulating agent
体外研究 (In Vitro)	Thriftyfasin 已在各种免疫功能障碍实验模型中显示出有效性，主要是在肝炎（土拨鼠）和流感（小鼠）等传染病以及黑色素瘤（小鼠）和结直肠癌（大鼠）等癌症中，该药物已证明具有抗肿瘤作用[2]。胸腺法新的作用机制尚未完全明确，但一般认为与其免疫调节活性相关，主要表现为增强T细胞功能。在多项体外实验中，胸腺肽α1可促进T细胞分化与成熟，例如CD4+、CD8+及CD3+细胞数量均被证实有所增加。胸腺肽α1还被证实可在丝裂原或抗原激活后提高IFN-γ、IL-2、IL-3的生成量及IL-2受体的表达水平，增强NK细胞活性，促进移动抑制因子（MIF）的产生，并提升对T细胞依赖性抗原的抗体反应。此外，胸腺肽α1在体外实验中还显示出可拮抗地塞米松诱导的胸腺细胞凋亡的作用。胸腺法新是一种由28个氨基酸组成的多肽，为人工合成产品，最初是从胸腺肽组分5（一种含多种免疫活性肽的牛胸腺提取物）中分离得到。体外研究表明，胸腺法新可促进T细胞的生成与成熟，刺激干扰素-γ、白细胞介素-2等Th1细胞因子的产生，并增强自然杀伤细胞的细胞毒性作用。
体内研究 (In Vivo)	胸腺法新已证明对一系列免疫功能障碍的实验模型有效，包括黑色素瘤（小鼠）和结直肠癌（大鼠），以及肝炎（土拨鼠）和流感（小鼠）等传染病。癌症，其中 thymusfaxin 已被证明具有抗癌特性 [2]。对经化疗、肿瘤负荷或放射治疗导致免疫抑制的动物给予胸腺肽α1的研究显示，该物质可减轻细胞毒性药物对骨髓的损伤，抑制肿瘤进展并降低机会性感染风险，从而延长存活时间、提高存活率。胸腺肽α1的诸多体外和体内效应，可被解释为影响多能干细胞向胸腺细胞的分化或促进胸腺细胞活化为活性T细胞的作用。体外实验还表明，胸腺法新可上调小鼠及人类树突状细胞中Toll样受体（包括TLR2与TLR9）的表达，并激活NF-κB与JNK/P38/AP1信号通路。胸腺法新对树突状细胞的激活作用，为其免疫调节和抗病毒效应提供了另一种可能的解释路径。本品适用于老年患者流感疫苗的辅助治疗，以及作为曾接受免疫但未能获得足够抗体滴度的慢性血液透析患者的流感疫苗和乙肝疫苗的辅助治疗。
药代性质 (ADME/PK)	吸收、分布和排泄吸收迅速，约2小时达到血清峰值浓度。生物半衰期约2小时。多次皮下注射后未见蓄积。
参考文献	[1]. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects. Apoptosis. 2015 Oct;20(10):1307-20. [2]. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol. 2004 Dec;19(12):S69-72.
其他信息	胸腺素肽是一种多肽。胸腺素肽是胸腺素α1的化学合成版本，与人胸腺素α1完全相同。胸腺素α1是一种乙酰化多肽。胸腺素α1目前已在35个发展中国家获批用于治疗乙型和丙型肝炎。它也被用于增强其他疾病的免疫反应。 EMZ702是一种无毒药物，与干扰素具有强大的抗病毒协同作用，是目前丙型肝炎标准治疗方案的理想联合用药。 EMZ702 具有极佳的安全性，在丙型肝炎替代模型中，EMZ702 与干扰素和利巴韦林联合用药的抗病毒效力比单独使用干扰素和利巴韦林提高了 2 至 3 倍。胸腺素α-1 是一种合成的胸腺素类似物，胸腺素α-1 是一种由前体蛋白原胸腺素α衍生的 28 个氨基酸的蛋白质。胸腺素α-1 具有多种免疫调节特性，可诱导小鼠 T 细胞前体和人胸腺细胞的分化，以及功能未成熟的脐带血淋巴细胞的终末分化，并诱导外周血单核细胞产生 IL-2、高亲和力 IL-2 受体和 B 细胞生长因子。辅助性 T 细胞和细胞毒性/抑制性 T 细胞是胸腺素作用的靶细胞。胸腺素α-1已被证实能提高巨噬细胞抗原呈递的效率，并且是α-凝血酶活性的内源性调节剂。(NCI04) 胸腺激素多肽，存在于胸腺素组分5（一种粗胸腺提取物）中，但现在可通过合成生产。胸腺素可单独使用或与干扰素联合使用，作为免疫调节剂用于治疗慢性乙型肝炎和丙型肝炎。胸腺素还用于治疗化疗引起的免疫抑制，并增强免疫功能低下患者流感疫苗和乙型肝炎疫苗的疗效。药物适应症适用于老年患者流感疫苗的佐剂，以及既往免疫接种后抗体滴度不足的慢性血液透析患者流感疫苗和乙型肝炎疫苗的佐剂。正在研究其在肝炎（病毒性、丙型肝炎）治疗中的应用/用途。作用机制胸腺素的作用机制尚未完全阐明，但被认为与其免疫调节活性有关，主要围绕增强T细胞功能。多种体外实验表明，胸腺素α1能够促进T细胞分化和成熟；例如，CD4+、CD8+和CD3+细胞的数量均有所增加。胸腺素α1还能在有丝分裂原或抗原激活后，增加IFN-γ、IL-2、IL-3的产生以及IL-2受体的表达，增强NK细胞活性，增加迁移抑制因子（MIF）的产生，并增强对T细胞依赖性抗原的抗体反应。此外，胸腺素α1还能在体外拮抗地塞米松诱导的胸腺细胞凋亡。在体内，对接受化疗、肿瘤负荷或放射治疗的免疫抑制动物给予胸腺素α1后发现，胸腺素α1能够保护骨髓免受细胞毒性损伤，抑制肿瘤进展和机会性感染，从而延长生存时间和提高存活动物的数量。许多体外和体内实验都表明，胸腺素α1对多能干细胞分化为胸腺细胞或激活胸腺细胞为活化T细胞具有影响。体外实验还显示，胸腺素α1能够上调小鼠和人树突状细胞中Toll样受体（TLR）的表达，包括TLR2和TLR9，并激活NF-κB和JNK/P38/AP1通路。胸腺素α1激活树突状细胞的机制为解释其免疫调节和抗病毒作用提供了另一种可能的途径。药效学胸腺素α1是一种由28个氨基酸组成的多肽，可通过人工合成获得，但最初是从牛胸腺提取物——胸腺素组分5中分离得到的，该组分含有多种免疫活性肽。体外研究表明，胸腺素能影响 T 细胞的产生和成熟，刺激 Th1 细胞因子（如干扰素-γ 和白细胞介素-2）的产生，并激活自然杀伤细胞介导的细胞毒性。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C129H215N33O55
分子量	3108.3
精确质量	3106.504
CAS号	62304-98-7
相关CAS号	62304-98-7(CATTLE) ; 69521-94-4(UNSPECIFIED)
PubChem CID	16130571
序列	N-acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH N-acetyl-L-seryl-L-alpha-aspartyl-L-alanyl-L-alanyl-L-valyl-L-alpha-aspartyl-L-threonyl-L-seryl-L-seryl-L-alpha-glutamyl-L-isoleucyl-L-threonyl-L-threonyl-L-lysyl-L-alpha-aspartyl-L-leucyl-L-lysyl-L-alpha-glutamyl-L-lysyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-valyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-alpha-glutamyl-L-asparagine
短序列	SDAAVDTSSEITTKDLKEKKEVVEEAEN; Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
外观&性状	White to off-white solid powder
密度	1.4±0.1 g/cm3
沸点	2899.7±65.0 °C at 760 mmHg
闪点	1707.5±34.3 °C
蒸汽压	0.0±0.6 mmHg at 25°C
折射率	1.563
LogP	-9.87
tPSA	1456.35
氢键供体(HBD)数目	49
氢键受体(HBA)数目	59
可旋转键数目(RBC)	111
重原子数目	217
分子复杂度/Complexity	7190
定义原子立体中心数目	32
SMILES	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C
InChi Key	NZVYCXVTEHPMHE-ZSUJOUNUSA-N
InChi Code	InChI=1S/C129H215N33O55/c1-18-59(10)98(159-114(201)76(36-42-91(181)182)146-120(207)83(53-164)154-121(208)84(54-165)155-127(214)99(63(14)166)160-118(205)80(51-94(187)188)152-123(210)95(56(4)5)156-104(191)62(13)135-102(189)60(11)137-115(202)78(49-92(183)184)151-119(206)82(52-163)138-66(17)169)125(212)161-101(65(16)168)128(215)162-100(64(15)167)126(213)147-70(30-22-26-46-133)109(196)150-79(50-93(185)186)117(204)149-77(47-55(2)3)116(203)142-69(29-21-25-45-132)108(195)144-73(33-39-88(175)176)110(197)141-67(27-19-23-43-130)106(193)140-68(28-20-24-44-131)107(194)145-75(35-41-90(179)180)113(200)157-97(58(8)9)124(211)158-96(57(6)7)122(209)148-74(34-40-89(177)178)111(198)143-71(31-37-86(171)172)105(192)136-61(12)103(190)139-72(32-38-87(173)174)112(199)153-81(129(216)217)48-85(134)170/h55-65,67-84,95-101,163-168H,18-54,130-133H2,1-17H3,(H2,134,170)(H,135,189)(H,136,192)(H,137,202)(H,138,169)(H,139,190)(H,140,193)(H,141,197)(H,142,203)(H,143,198)(H,144,195)(H,145,194)(H,146,207)(H,147,213)(H,148,209)(H,149,204)(H,150,196)(H,151,206)(H,152,210)(H,153,199)(H,154,208)(H,155,214)(H,156,191)(H,157,200)(H,158,211)(H,159,201)(H,160,205)(H,161,212)(H,162,215)(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H,181,182)(H,183,184)(H,185,186)(H,187,188)(H,216,217)/t59-,60-,61-,62-,63+,64+,65+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,95-,96-,97-,98-,99-,100-,101-/m0/s1
化学名	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-6-aminohexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-5-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-oxopentanoic acid
别名	Zadaxin; Thymosin alpha1; Thymosin alpha 1; alpha1-Thymosin; Thymosin-alpha-1;
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意：请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	H2O : ~0.3 mg/mL (~0.10 mM)
溶解度 (体内实验)	配方 1 中的溶解度: 100 mg/mL (32.17 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

H2O : ~0.3 mg/mL (~0.10 mM)

溶解度 (体内实验)

配方 1 中的溶解度: 100 mg/mL (32.17 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	0.3217 mL	1.6086 mL	3.2172 mL
	5 mM	0.0643 mL	0.3217 mL	0.6434 mL
	10 mM	0.0322 mL	0.1609 mL	0.3217 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Title:Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
Status:Completed
updateDate:2026-04-21
Ctid:NCT04428008

Link: https://clinicaltrials.gov/ct2/show/NCT04428008

Conditions:COVID-19
Interventions:Thymalfasin
Phase:Phase 2

Title:Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Status:Recruiting
updateDate:2026-03-03
Ctid:NCT06461910

Link: https://clinicaltrials.gov/ct2/show/NCT06461910

Conditions:Gastric Cancer|Esophagogastric Junction Adenocarcinoma
Interventions:Tegafur
Phase:Phase 2

Title:The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Status:Active, not recruiting
updateDate:2025-11-17
Ctid:NCT06139419

Link: https://clinicaltrials.gov/ct2/show/NCT06139419

Conditions:Non-small Cell Lung Cancer
Interventions:Thymosin Alpha1
Phase:Phase 2

View More

Title:Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
Status:Recruiting
updateDate:2025-07-31
Ctid:NCT06821100

Link: https://clinicaltrials.gov/ct2/show/NCT06821100

Conditions:Vaccine Response|COVID-19 Vaccine|Immune Response to Covid 19 Vaccination
Interventions:Thymalfasin (Thymosin alpha 1, Ta1)
Phase:Phase 1

Title:Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Status:Active, not recruiting
updateDate:2025-04-02
Ctid:NCT06056804

Link: https://clinicaltrials.gov/ct2/show/NCT06056804

Conditions:Locally Advanced Rectal Cancer
Interventions:thymalfasin
Phase:Phase 2

Title:'Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer'
Status:Recruiting
updateDate:2025-02-17
Ctid:NCT06829355

Link: https://clinicaltrials.gov/ct2/show/NCT06829355

Conditions:MCRC
Interventions:Tislelizumab (BGB-A317)
Phase:Phase 2

Title:Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Status:Not yet recruiting
updateDate:2024-09-23
Ctid:NCT06607926

Link: https://clinicaltrials.gov/ct2/show/NCT06607926

Conditions:Resectable Non-Small-Cell Lung Cancer
Interventions:Platinum-doublet chemotherapy
Phase:N/A

Title:Immuno-effect of Tα1 for Stage I NSCLC
Status:Recruiting
updateDate:2024-09-19
Ctid:NCT06598839

Link: https://clinicaltrials.gov/ct2/show/NCT06598839

Conditions:Non Small Cell Lung Cancer
Interventions:Thymosin Alpha1
Phase:N/A

Title:Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Status:Not yet recruiting
updateDate:2024-08-27
Ctid:NCT06573398

Link: https://clinicaltrials.gov/ct2/show/NCT06573398

Conditions:Carcinoma, Pancreatic Ductal
Interventions:SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
Phase:Phase 2

Title:Thymosin Alpha-1 for irAE Secondary to ICIs
Status:Unknown status
updateDate:2023-12-20
Ctid:NCT06178146

Link: https://clinicaltrials.gov/ct2/show/NCT06178146

Conditions:IrAE
Interventions:Immunosuppressant
Phase:Phase 4

Title:Abscopal Effect for Metastatic Colorectal Cancer
Status:Withdrawn
updateDate:2023-09-21
Ctid:NCT02535988

Link: https://clinicaltrials.gov/ct2/show/NCT02535988

Conditions:Colorectal Cancer|Metastatic Colorectal Cancer|Thymalfasin
Interventions:Thymalfasin
Phase:Phase 2

Title:Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
Status:Unknown status
updateDate:2023-09-06
Ctid:NCT06024356

Link: https://clinicaltrials.gov/ct2/show/NCT06024356

Conditions:Colorectal Neoplasms
Interventions:Thymalfasin
Phase:

Title:Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
Status:Completed
updateDate:2023-07-18
Ctid:NCT04963712

Link: https://clinicaltrials.gov/ct2/show/NCT04963712

Conditions:HIV-1-infection
Interventions:Zadaxin
Phase:Early Phase 1

Title:The Efficacy and Safety of Ta1 for Sepsis
Status:Completed
updateDate:2023-04-10
Ctid:NCT02867267

Link: https://clinicaltrials.gov/ct2/show/NCT02867267

Conditions:Sepsis
Interventions:Thymosin alpha 1
Phase:Phase 3

Title:Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Status:Unknown status
updateDate:2023-03-30
Ctid:NCT05790447

Link: https://clinicaltrials.gov/ct2/show/NCT05790447

Conditions:Advanced Solid Tumor|Refractory Tumor
Interventions:GM-CSF
Phase:Phase 2

Title:Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
Status:Terminated
updateDate:2023-02-14
Ctid:NCT04487444

Link: https://clinicaltrials.gov/ct2/show/NCT04487444

Conditions:Covid19
Interventions:Thymalfasin
Phase:Phase 2

Title:Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
Status:Unknown status
updateDate:2022-08-04
Ctid:NCT05487469

Link: https://clinicaltrials.gov/ct2/show/NCT05487469

Conditions:Rheumatic Heart Disease|Cardiopulmonary Bypass|Immunotherapy
Interventions:Thymosin Alpha1
Phase:N/A

Title:Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
Status:Completed
updateDate:2022-01-03
Ctid:NCT03659578

Link: https://clinicaltrials.gov/ct2/show/NCT03659578

Conditions:Non-small Cell Lung Cancer
Interventions:thymosin alpha 1
Phase:Phase 2

Title:Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Status:Recruiting
updateDate:2021-10-21
Ctid:NCT05086614

Link: https://clinicaltrials.gov/ct2/show/NCT05086614

Conditions:Stage II Colorectal Cancer|Stage III Colorectal Cancer
Interventions:Thymosin Alpha1
Phase:Phase 3

Title:Long-term Prognosis of Patients With Sepsis After Immunotherapy
Status:Not yet recruiting
updateDate:2021-05-25
Ctid:NCT04901104

Link: https://clinicaltrials.gov/ct2/show/NCT04901104

Conditions:Long-term Effects of Thymosin Alpha 1 Treatment
Interventions:Thymosin Alpha1
Phase:

Title:Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis
Status:Completed
updateDate:2021-04-05
Ctid:NCT02473406

Link: https://clinicaltrials.gov/ct2/show/NCT02473406

Conditions:Pancreatitis, Acute Necrotizing
Interventions:normal saline
Phase:Phase 4

Title:Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
Status:Unknown status
updateDate:2020-08-26
Ctid:NCT04524169

Link: https://clinicaltrials.gov/ct2/show/NCT04524169

Conditions:Osteoporotic Pain
Interventions:Thymosin Alpha1
Phase:Phase 4

Title:Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
Status:Unknown status
updateDate:2020-03-31
Ctid:NCT04320238

Link: https://clinicaltrials.gov/ct2/show/NCT04320238

Conditions:2019 Novel Coronavirus Infection
Interventions:thymosin alpha 1
Phase:Phase 3

Title:Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
Status:Completed
updateDate:2019-10-18
Ctid:NCT00230854

Link: https://clinicaltrials.gov/ct2/show/NCT00230854

Conditions:Chronic Hepatitis C|Hepatitis, Viral, Human
Interventions:EMZ702
Phase:Phase 1

Title:Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis
Status:Completed
updateDate:2019-04-04
Ctid:NCT02883595

Link: https://clinicaltrials.gov/ct2/show/NCT02883595

Conditions:Sepsis
Interventions:thymosin alpha 1
Phase:Phase 4

Title:Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
Status:Withdrawn
updateDate:2019-03-26
Ctid:NCT02542930

Link: https://clinicaltrials.gov/ct2/show/NCT02542930

Conditions:Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Radiotherapy|Thymalfasin
Interventions:Thymalfasin
Phase:Phase 2

Title:Abscopal Effect for Metastatic Small Cell Lung Cancer
Status:Withdrawn
updateDate:2019-03-21
Ctid:NCT02542137

Link: https://clinicaltrials.gov/ct2/show/NCT02542137

Conditions:Small Cell Lung Cancer|Radiotherapy|Thymalfasin
Interventions:Thymalfasin
Phase:Phase 2

Title:The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial
Status:Completed
updateDate:2018-04-26
Ctid:NCT03509688

Link: https://clinicaltrials.gov/ct2/show/NCT03509688

Conditions:Hepatitis
Interventions:entecavir+thymosin α1
Phase:N/A

Title:Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients
Status:Unknown status
updateDate:2018-02-28
Ctid:NCT03448744

Link: https://clinicaltrials.gov/ct2/show/NCT03448744

Conditions:Chronic Hepatitis b
Interventions:Entecavir
Phase:Phase 4

Title:SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Status:Unknown status
updateDate:2017-11-28
Ctid:NCT02545751

Link: https://clinicaltrials.gov/ct2/show/NCT02545751

Conditions:Esophageal Cancer|Metastatic Esophageal Cancer|Stereotactic Body Radiation Therapy|Thymalfasin
Interventions:Thymalfasin
Phase:Phase 2

Title:Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
Status:Unknown status
updateDate:2016-11-25
Ctid:NCT02787447

Link: https://clinicaltrials.gov/ct2/show/NCT02787447

Conditions:Lung Adenocarcinoma
Interventions:Thymosin Alpha 1
Phase:Phase 2

Title:Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
Status:Unknown status
updateDate:2016-09-19
Ctid:NCT02906150

Link: https://clinicaltrials.gov/ct2/show/NCT02906150

Conditions:Non-Small Cell Lung Cancer
Interventions:SoC (chemotherapy and platinum agent)
Phase:Phase 2

Title:First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Status:Unknown status
updateDate:2016-09-19
Ctid:NCT02906163

Link: https://clinicaltrials.gov/ct2/show/NCT02906163

Conditions:EGFR Mutation Positive Non Small Cell Lung Cancer
Interventions:SoC (tyrosine kinase inhibitor)
Phase:Phase 1/Phase 2

Title:Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Status:Completed
updateDate:2016-01-05
Ctid:NCT02646189

Link: https://clinicaltrials.gov/ct2/show/NCT02646189

Conditions:Hepatitis B, Chronic
Interventions:Pegasys
Phase:Phase 1/Phase 2

Title:Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
Status:Unknown status
updateDate:2014-11-21
Ctid:NCT02281266

Link: https://clinicaltrials.gov/ct2/show/NCT02281266

Conditions:Curable Hepatitis B Virus-Related Hepatocellular Carcinoma
Interventions:nucleoside analog (suggest to use entecavir)
Phase:Phase 4

Title:A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
Status:Completed
updateDate:2012-03-29
Ctid:NCT01031966

Link: https://clinicaltrials.gov/ct2/show/NCT01031966

Conditions:END STAGE RENAL DISEASE
Interventions:Thymosin alpha 1
Phase:Phase 2

Title:Efficacy of Thymosin alpha1 for Severe Sepsis
Status:Completed
updateDate:2011-06-14
Ctid:NCT00711620

Link: https://clinicaltrials.gov/ct2/show/NCT00711620

Conditions:Severe Sepsis
Interventions:Thymosin alpha 1
Phase:N/A

Title:Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
Status:Completed
updateDate:2010-08-10
Ctid:NCT01178996

Link: https://clinicaltrials.gov/ct2/show/NCT01178996

Conditions:Chronic Hepatitis C
Interventions:Placebo
Phase:Phase 3

Title:Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
Status:Completed
updateDate:2009-07-09
Ctid:NCT00911443

Link: https://clinicaltrials.gov/ct2/show/NCT00911443

Conditions:Malignant Melanoma
Interventions:Dacarbazine + Interferon alpha
Phase:Phase 2

Title:The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
Status:Completed
updateDate:2008-07-30
Ctid:NCT00001036

Link: https://clinicaltrials.gov/ct2/show/NCT00001036

Conditions:HIV Infections
Interventions:Zidovudine
Phase:Phase 1

Title:Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Status:Completed
updateDate:2008-01-15
Ctid:NCT00039962

Link: https://clinicaltrials.gov/ct2/show/NCT00039962

Conditions:Hepatitis C|Hepatitis C, Chronic
Interventions:PEGinterferon alfa-2a
Phase:Phase 3

Title:A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
Status:Completed
updateDate:2008-01-15
Ctid:NCT00082082

Link: https://clinicaltrials.gov/ct2/show/NCT00082082

Conditions:Carcinoma, Hepatocellular
Interventions:Thymalfasin (thymosin alpha-1)
Phase:Phase 2

Title:Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
Status:Unknown status
updateDate:2007-12-24
Ctid:NCT00580450

Link: https://clinicaltrials.gov/ct2/show/NCT00580450

Conditions:Hematological Malignancies
Interventions:Thymosin alpha 1
Phase:Phase 1/Phase 2

Title:A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY
Status:Ongoing
Date:2005-01-20
Eudractnumber:2004-001927-39

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001927-39

Condition:TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY
Phase:Phase 2

Title:A Phase III, Multicentre, Double Blinded Study in Patients with Chronic Hepatitis C who are Non-responders to prior PEGinterferon alpha + Ribavirin Therapy Comparing Treatment with Thymosin alpha 1 + PEGinterferon alfa-2a plus Ribavirin with PEGinterferon alfa-2a + Ribavirin + Placebo
Status:Ongoing
Date:2004-09-27
Eudractnumber:2004-001277-25

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001277-25

Condition:Treatment of Patients with Chronic Hepatitis C who are Non-responders to a course with approved doses of PEGinterferon alpha + RibavirinTrattamento di pazienti affetti da epatite C cronica refrattari alla terapia di prima linea al dosaggio approvato di peg-interferone alfa + ribavirina
Phase:Phase 3